

Cangene Corporation
155 Innovation Drive
Winnipeg, MB,
Canada R3T 5Y3



Dear Healthcare Provider:

Subject: WinRho® SDF [Rh₀(D) Immune Globulin (Human) for Injection] Healthcare Provider and Patient Educational Materials Kit.

Cangene Corporation, the manufacturer of WinRho® SDF [Rh₀(D) Immune Globulin (Human) for Injection], is pleased to present you with a **WinRho® SDF Healthcare Provider and Patient Educational Materials Kit**. This kit was developed to support the WinRho® SDF risk management plan (RMP) requested by Health Canada. The WinRho® SDF educational material kit is intended to assist you in identifying the proper patient for WinRho therapy. The kit is also designed to educate both you and your patients about the serious risks associated with WinRho® SDF for treatment of ITP as well as other safety considerations.

The kit includes the following materials:



- **WinRho® SDF Healthcare Provider Brochure:** The brochure describes the appropriate population of ITP patients for whom WinRho® SDF should be prescribed, including indications for use, contraindications and warnings. In addition, the brochure includes a patient selection checklist and risk minimization algorithm providing WinRho® SDF patient selection information, signs and symptoms of acute hemolytic reactions such as intravascular hemolysis (IVH) and their complications, monitoring instructions and potential diagnostic and treatment options for management of complications.
- **WinRho® SDF Patient Education Tear Pad:** This tear pad is intended for both you and your patients and includes following two pieces:
 - **WinRho® SDF Patient Information Sheet (upper portion):** This sheet is a tool to assist you in explaining the safety information to your patient and can be provided to the patient upon discharge after the 8 hour observation period.
 - **WinRho® SDF Patient Alert Card (lower portion):** This card outlines the list of signs and symptoms of IVH, instructions for the self- monitoring for the signs/symptoms of IVH and contact information for the healthcare provider. The completed patient alert card can be provided to your patient upon discharge after the 8 hour observation period and may be helpful to emergency room physicians should the patient present to casualty with an acute hemolytic reaction.

We request that you and/or your staff review these pieces with your ITP patients treated with WinRho® SDF. Please ensure that your patients understand the safety profile of WinRho® SDF and the self-monitoring instructions following WinRho® SDF administration for treatment of ITP.

Electronic copies of WinRho® SDF healthcare provider and patient educational materials kit are available on www.winrho.ca. To order more hard copies of WinRho® SDF healthcare provider and patient educational materials kit, please contact Cangene Corporation:

Email: medicalaffairs@cangene.com

Phone: 1-800-768-2304

Sincerely,

Deepak Jain, MD, MBA
Manager, Medical Affairs
Cangene Corporation

WINRHO[®]SDF
Rh₀(D) Immune Globulin
(Human) for Injection

Healthcare Provider Brochure

WINRHO[®]SDF

Rh₀(D) Immune Globulin
(Human) for Injection



Overview

This brochure has been developed as part of a plan to help reduce the risk of serious adverse reactions and maximize the benefit-risk profile of WinRho[®] SDF for the treatment of immune thrombocytopenic purpura (ITP). **For more detailed safety information, refer to WinRho[®] SDF Package Insert.**

On rare occasions when WinRho[®] SDF is used for the treatment of ITP, adverse reactions collectively referred to as acute

hemolytic reactions (AHR) may occur, such as intravascular hemolysis (IVH). AHRs may in turn have serious sequelae which have in some instances been fatal.

The purpose of this brochure is to ensure that healthcare professionals treating ITP patients with WinRho[®] SDF are able to identify patients in whom WinRho[®] SDF use should be avoided or is generally not recommended. This brochure also provides information on how to treat the complications related to IVH.

Contents:

- 1 Indications and Usage
- 2 Contraindications
- 3 Warning
- 4 Patient Selection Checklist
- 5 Risk Assessment and Management Algorithm

Please see Important Safety Information, including Boxed Warning and accompanying full Prescribing Information.

1 Indications and Usage

Treatment of ITP

WinRho® SDF must be administered via the intravenous route when used in the treatment of ITP in the following non-splenectomized Rh₀ (D) positive patient populations:

- ▶ Children with chronic or acute ITP
- ▶ Adults with chronic ITP, or
- ▶ Children and adults with ITP secondary to HIV infection

2 Contraindications

WinRho® SDF should not be administered to patients:

- ▶ Who are Rh₀ (D) negative
- ▶ Who are splenectomized
- ▶ With ITP secondary to other conditions including leukemia, lymphoma, or active viral infections with EBV or HCV
- ▶ Who are elderly with underlying cardiac, renal or hepatic co-morbidities predisposing to complications of acute hemolytic reactions (AHR)
- ▶ With evidence of autoimmune hemolytic anemia (Evan's Syndrome), Systemic Lupus Erythematosus (SLE) or anti phospholipid antibody syndrome (APS)
- ▶ With a history of anaphylactic or other severe systemic reaction to human immune globulins
- ▶ Who are IgA deficient
- ▶ Who are hypersensitive to this drug or to any ingredient in the drug formulation or component of the container

3 Warning

WinRho® SDF should be prescribed with extreme caution in patients with following conditions:

- ▶ Patients of advanced age (> 65 years) with underlying cardiac, renal or hepatic co-morbidities are at increased risk of developing serious renal, hepatic or cardiovascular complications if they develop IVH
- ▶ Pre-existing risk factors for thrombotic events including age over 65, hypertension, diabetes mellitus and a history of vascular disease including ischemic disorders or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilisation, or severely hypovolemic patients
- ▶ Pre-existing risk factors for acute renal failure including existing renal insufficiency, diabetes mellitus, hypovolemia, overweight, sepsis, concomitant administration of nephrotoxic medicinal products or age over 65

Physicians are advised that if a patient has evidence of hemolysis (reticulocytosis greater than 3%) or is at high risk for hemolysis (positive DAT not attributed to previous immune globulin administration), alternative therapies must be used.

4

Patient Selection Checklist

Potential candidate for WinRho® SDF [Rh₀(D) Immune Globulin (Human) for Injection]

- ✓ Primary ITP
- ✓ < 65 years of age
- ✓ > 65 years of age if patient does not suffer from cardiac, renal or hepatic co-morbidities
- ✓ Rh₀(D) positive and non-splenectomized

Recommended lab tests/results before initiating WinRho® SDF therapy:

- ✓ Blood type and count
- ✓ Negative direct antiglobulin test (DAT or Coombs' Test)
- ✓ Hemoglobin > 8 g/dL*
- ✓ Reticulocyte count < 3%†
- ✓ Dipstick urinalysis

* A reduced dose of WinRho SDF is recommended for patients with hemoglobin levels of 8–10 g/dL due to risk of hemolysis

† If reticulocyte count is >3%, other treatments should be used

WinRho® SDF should not be administered to patients with:


- ✗ Pre-existing hemolytic conditions
 - Autoimmune hemolytic anemia (Evans Syndrome)
 - Systemic lupus erythematosus (SLE)
 - Antiphospholipid antibody syndrome (APS)
- ✗ ITP secondary to other conditions that include:
 - Leukemia or lymphoma
 - Active infections (other than HIV) including HCV

WinRho SDF is contraindicated in patients of advanced age (65 and over) with co-morbid conditions.

This list of criteria is for guidance only and does not replace a complete physician's assessment.



5 Risk Management & Assessment Algorithm



Direction for Healthcare Provider: Patient Information Sheet should be given to the patient after each infusion of WinRho® SDF for the treatment of Immune Thrombocytopenic Purpura (ITP)



Patient Information Sheet

WinRho® SDF (pronounced win-row - S-D-F)

You should read this Patient Information Sheet carefully each time before you are scheduled to receive a WinRho® SDF treatment for Immune Thrombocytopenic Purpura (ITP). This sheet is a summary of the important information you need to know about WinRho® SDF, and does not take the place of talking with your doctor; it does not contain all of the information available about WinRho® SDF. If you have any questions after reading this information sheet, make sure you ask your doctor or nurse.

1 What is the most important information you should know about WinRho® SDF?

Due to the way WinRho® SDF is believed to work, a minimal decrease in the amount of red blood cells is expected after treatment with WinRho® SDF. However, a small number of patients have experienced a reaction in which a large number of red blood cells are destroyed while in the blood vessels. This condition is called Intravascular Hemolysis (IVH) and in rare circumstances it could lead to serious illness or death. To decrease the risk of having a severe reaction, you need to remain under observation in a healthcare setting for at least 8 hours following each treatment with WinRho® SDF and your doctor will ask for blood and urine tests before and after infusion with WinRho® SDF and before you leave the healthcare setting.

Reactions usually occur within 4 to 8 hours after getting an infusion. Tell or contact your doctor or healthcare provider right away if you experience any of the following signs or symptoms after receiving a WinRho® SDF infusion:

- shaking chills, fever or back pain,
- discoloured or darkened urine,
- decreased urine production,
- swelling,
- shortness of breath.

You should continue to monitor for these reactions for the next 72 hours after each treatment with WinRho® SDF.

WinRho® SDF contains maltose, which can give false readings on some glucose testing meters. If you are diabetic, ask your doctor what types of glucose testing meters can be used safely while you are getting WinRho® SDF.

2 What is WinRho® SDF?

WinRho® SDF is a protein product, called “immune globulin,” which is made from human plasma. It has antibodies to the “D” antigen that people with “Rh-positive” blood have in their blood. WinRho® SDF is used to increase the number of platelets in the blood of Rh-positive people who have a disorder called immune thrombocytopenic purpura (ITP). People with ITP bruise and bleed easily because they have a very low number of platelets in their blood.

WinRho® SDF is also used to treat Rh-negative girls and women who:

- need a blood transfusion using Rh-positive blood
- are carrying an Rh-positive baby



Detach Alert Card below, fold where creased and keep with you while monitoring your treatment.

To the Physician:

- There have been rare serious (sometimes fatal) adverse events of intravascular hemolysis (IVH) and its complications which have been reported following ITP treatment with WinRho® SDF. Perform an Urine Dipstick/Microscopic examination on the urine specimen patient has brought in.
- The most important clinical sign of IVH is hemoglobinuria (free hemoglobin in urine) or hemoglobinemia (free hemoglobin in serum/plasma)
- Patients with large degrees of hemolysis are at risk for developing
 - Hemolytic Anemia and potential sequelae of ARDS, Congestive Heart Failure and Pulmonary Edema
 - Renal Insufficiency/Renal Failure Disseminated Intravascular Coagulation

If urine is positive for blood or hemoglobin the following tests may assist in the diagnosis and management of patient:

- Plasma Hemoglobin
- Plasma Haptoglobin
- LDH, Bilirubin (Total, Direct)
- Creatinine, Urea (BUN)
- Fibrin Degredation Products or D-Dimer
- EKG, Chest X-ray

Patient Alert Card
WinRho® SDF



Direction for Healthcare provider:

Completed Patient Alert Card should be given to the patient after each infusion of WinRho® SDF for the treatment of Immune Thrombocytopenic Purpura (ITP)

Patient's Name: _____

Doctor's Name: _____

Doctor's Phone: _____

Dose of WinRho SDF administered: _____ IU

Date Administered: _____

Lot Number: _____

3 Who should not use WinRho[®]SDF?

You should not use WinRho[®] SDF for the treatment of ITP if you:

- have ever had a severe allergic reaction (such as trouble breathing, hives, passing out) after getting any blood product or blood product transfusion
- have an immune globulin A (IgA) deficiency
- have Rh-negative blood
- have had your spleen removed
- have leukemia, lymphoma
- have active viral infections such as Hepatitis C or Epstein Barr Virus (EBV)
- are more 65 years of age with conditions affecting your heart, kidneys or liver
- have certain conditions affecting the immune system such as: Systemic Lupus Erythematosus (SLE), or immune destruction of red blood cells and a condition called anti-phospholipid syndrome.



4 How will I get WinRho[®]SDF?

Your doctor will give you WinRho[®] SDF as an intravenous injection. For the treatment of ITP it will usually take 5 to 20 minutes for an injection. The doctor will decide if you need one or more injections.

5 What should I avoid while using WinRho[®]SDF?

You should not be vaccinated with live viruses such as found in measles, mumps and yellow fever vaccines.

WinRho[®] SDF can interfere with certain blood tests. It is important to tell the healthcare provider taking blood samples and the doctor that you got WinRho[®] SDF treatment.

6 What are the possible side effects of WinRho[®]SDF?

The most common side effects of WinRho[®] SDF are:

- headache
- chills
- fever
- weakness
- diarrhea
- nausea and vomiting
- achy muscles
- feeling light-headed or dizziness
- fainting
- flushing
- rash
- sweating

Tell your doctor right away if you have:

- fever over 100°F
- a painful lump or swelling (because this may be a sign of a blood clot)
- oddly coloured urine
- severe back pain
- swelling, especially around the ankles
- shortness of breath
- shaking or chills that continue or get worse
- bruising that is increasing in diameter (because this may be a sign of a clotting problem)
- trouble urinating
- severe abdominal pain
- hives

Talk to your doctor about any side effects that concern you.

You may report side effects to Cangene Corporation at **1-800-768-2304** or Health Canada reporting system by phone **1-866-234-2345**



Cangene Corporation
Winnipeg, Manitoba
Canada R3T 5Y3

Detach Alert Card below, fold where creased and keep with you while monitoring your treatment.

To the Patient:

This alert card contains important safety information about WinRho[®] SDF

A small number of patients on WinRho[®] SDF therapy have experienced a reaction in which a large number of red blood cells are destroyed while in the blood vessels leading to serious illness or death.

It is very important that you pay close attention to following signs or symptoms within 72 hours of your treatment.

- Shaking chills, fever or back pain,
- Discoloured or darkened urine,
- Decreased urine production,
- Swelling,
- Shortness of breath

If you experience any of above signs or symptoms, seek medical attention immediately

Monitoring at Home

After your WinRho[®] SDF treatment you will be sent home with the following instructions:

- For 72 hours after your treatment collect some urine in a clear container every time you pass urine
- Carefully examine the urine in the container for the following
 - ▶ Pink or red coloured urine
 - ▶ Dark urine the colour of tea or cola
- If urine is pink or dark, save the urine and immediately contact your physician/clinic or bring the urine container to the emergency department of your hospital.
- Show this card to hospital staff

Manufacturer:



Cangene Corporation
Winnipeg, Manitoba
Canada R3T 5Y3



For more information
(1-800-768-2304)
www.winrho.ca

To the Physician:

- There have been rare serious (sometimes fatal) adverse events of intravascular hemolysis (IVH) and its complications which have been reported following ITP treatment with WinRho® SDF. Perform an Urine Dipstick/Microscopic examination on the urine specimen patient has brought in.
- The most important clinical sign of IVH is hemoglobinuria (free hemoglobin in urine) or hemoglobinemia (free hemoglobin in serum/plasma)
- Patients with large degrees of hemolysis are at risk for developing
 - ▶ Hemolytic Anemia and potential sequelae of ARDS, Congestive Heart Failure and Pulmonary Edema
 - ▶ Renal Insufficiency/Renal Failure Disseminated Intravascular Coagulation

If urine is positive for blood or hemoglobin the following tests may assist in the diagnosis and management of patient:

- Plasma Hemoglobin
- Plasma Haptoglobin
- LDH, Bilirubin (Total, Direct)
- Creatinine, Urea (BUN)
- Fibrin Degredation Products or D-Dimer
- EKG, Chest X-ray

Patient Alert Card WinRho® SDF

WINRHO[®]SDF
Rh₀(D) Immune Globulin
(Human) for Injection

Direction for Healthcare provider:

Completed Patient Alert Card should be given to the patient after each infusion of WinRho® SDF for the treatment of Immune Thrombocytopenic Purpura (ITP)

Patient's Name: _____

Doctor's Name: _____

Doctor's Phone: _____

Dose of WinRho SDF administered: _____ IU

Date Administered: _____

Lot Number: _____

To the Patient:

This alert card contains important safety information about WinRho® SDF

A small number of patients on WinRho® SDF therapy have experienced a reaction in which a large number of red blood cells are destroyed while in the blood vessels leading to serious illness or death.

It is very important that you pay close attention to following signs or symptoms within 72 hours of your treatment.

- Shaking chills, fever or back pain,
- Discoloured or darkened urine,
- Decreased urine production,
- Swelling,
- Shortness of breath

If you experience any of above signs or symptoms, seek medical attention immediately

Monitoring at Home

After your WinRho® SDF treatment you will be sent home with the following instructions:

- For 72 hours after your treatment collect some urine in a clear container every time you pass urine
- Carefully examine the urine in the container for the following
 - ▶ Pink or red coloured urine
 - ▶ Dark urine the colour of tea or cola
- If urine is pink or dark, save the urine and immediately contact your physician/clinic or bring the urine container to the emergency department of your hospital.
- Show this card to hospital staff

Manufacturer:

CANGENE

Cangene Corporation
Winnipeg, Manitoba
Canada R3T 5Y3

For more information

(1-800-768-2304)

www.winrho.ca

WINRHO[®]SDF
Rh₀(D) Immune Globulin
(Human) for Injection